With March bringing significant volatility for ASX stocks, there is plenty of opportunity for value investors.
Unsurprisingly, much of the opportunity lies with ASX healthcare and technology stocks that have struggled over the past year.
For context, the S&P/ASX 200 Health Care Index (ASX: XHJ) is down 30% in the last 12 months.
The S&P ASX All Technology Index (ASX: XTX) is down 20% in that same span.
Meanwhile, the benchmark S&P/ASX 200 Index (ASX: XJO) is up 11.2%.
With that in mind, here are three ASX stocks drawing price targets from brokers indicating significant upside.
Image source: Getty Images
WiseTech Global Ltd (ASX: WTC)
WiseTech shares have been hotly covered recently as the company has clawed back some momentum after enduring a 60% fall in the back half of last year.
Positive earnings results in February have started to turn the tide for this technology company.
The Motley Fool's Grace Alvino laid out the compelling case for WiseTech shares last week, with AI tailwinds, market positioning and leadership all pointing towards a year of growth.
Brokers are also anticipating a strong recovery during 2026.
The logistics software company closed trading last week at $47.57 each.
15 analysts forecasts via TradingView have an average one year price target of $85.95, with the highest estimates reaching $123.83.
These targets indicate upside between 80% and 160%.
CSL Ltd (ASX: CSL)
CSL is another ASX stock that brokers remain positive on, despite a rough 12 months.
The Australian-based global biotechnology company has seen its share price fall 43% over the last year, and now sits close to its 52-week low.
On Friday, it closed trading at $141.03.
However, Morgans recently put a buy rating and $241.34 price target on the ASX healthcare stock.
This indicates upside of 71%.
Pro Medicus Ltd (ASX: PME)
Another struggling ASX healthcare stock tipped to recover is Pro Medicus.
The company provides medical imaging technology globally.
Its share price is down more than 42% in the last year.
However, it signed two key five year contracts last week.
Specifically, the company's wholly owned US subsidiary, Visage Imaging, signed two five-year contract renewals with a combined minimum value of $40 million.
It's possible this marks the beginning of a rebound.
It closed last week at $133.00.
However, 13 analyst ratings via TradingView have an average one year price target of $218.44.
This indicates 64% potential upside.
